Please ensure Javascript is enabled for purposes of website accessibility

Biogen's New Alzheimer's Drug Will Cost $56,000 Per Year

By Todd Campbell - Jun 7, 2021 at 5:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Biogen set the list price for Aduhelm, its newly approved treatment, and is collaborating with CVS to improve screening for the disease.

After securing Food and Drug Administration approval for the use of aducanumab in Alzheimer's disease patients, Biogen (BIIB 1.27%) announced the drug will cost $56,000 per year. Separately, the company also announced it's collaborating with CVS Health (CVS 2.05%) to make cognitive screenings more readily available in urban markets.

A man wearing a face mask shows the inside of his empty pants pockets.

Image source: Getty Images.

The FDA's approval of aducanumab, which will be sold under the brand name Aduhelm, was granted even though the agency's advisory committee recommended against approval last fall because of insufficient indications of efficacy. 

Aduhelm aims to reduce Alzheimer's symptoms by reducing amyloid beta plaque buildups believed to contribute to disease progression. However, it failed to hit its primary endpoint in one pivotal clinical trial, and the application for approval was based on a post-hoc analysis.

Although Aduhelm's list price is $56,000 per year, insurers typically negotiate discounts that could significantly reduce the cost. For example, Biogen says it's working with Cigna (CI 1.72%) to make Aduhelm available via a valued-based contract, with pricing determined by how well a patient responds to it.

Separately, Biogen announced it's working with CVS Health to increase patient testing within minority and underserved communities to improve early diagnosis. The companies plan to begin offering screenings in cities including Atlanta; Boston; Charlotte, North Carolina; Charleston, South Carolina; Chicago; Dallas; Detroit;, Houston; Los Angeles; Miami; New York City; Philadelphia; and Washington, D.C., in September.

 

Todd Campbell has no position in any of the stocks mentioned. His clients may or may not have positions in the stocks mentioned. The Motley Fool recommends Biogen and CVS Health. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$220.99 (1.27%) $2.77
CVS Health Corporation Stock Quote
CVS Health Corporation
CVS
$106.39 (2.05%) $2.14
Cigna Corporation Stock Quote
Cigna Corporation
CI
$290.92 (1.72%) $4.92

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.